MARKET

BBOT

BBOT

BridgeBio Oncology Therapeutics, Inc
NASDAQ
10.70
+0.55
+5.42%
After Hours: 10.60 -0.1 -0.93% 19:05 02/06 EST
OPEN
10.50
PREV CLOSE
10.15
HIGH
11.55
LOW
10.22
VOLUME
520.90K
TURNOVER
--
52 WEEK HIGH
14.87
52 WEEK LOW
8.50
MARKET CAP
855.88M
P/E (TTM)
53.58
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BBOT last week (0126-0130)?
Weekly Report · 5d ago
Weekly Report: what happened at BBOT last week (0119-0123)?
Weekly Report · 01/26 10:31
Weekly Report: what happened at BBOT last week (0112-0116)?
Weekly Report · 01/19 10:38
BridgeBio Oncology Therapeutics Grants Inducement Stock Options Under 2025 Plan
Reuters · 01/13 21:05
BRIDGEBIO ONCOLOGY THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 01/13 21:05
Weekly Report: what happened at BBOT last week (0105-0109)?
Weekly Report · 01/12 10:37
BridgeBio Oncology gains outperform rating from Raymond James
Seeking Alpha · 01/09 20:59
BridgeBio Oncology Price Target Announced at $24.00/Share by Raymond James
Dow Jones · 01/09 14:19
More
About BBOT
Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing the pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. Its pipeline of RAS-targeted oncology drug candidates includes BBO-8520, BBO-10203, and BBO-11818. BBO-8520 (NCT06343402) is a direct inhibitor of KRASG12C in both the ON and OFF states that is being evaluated both as monotherapy and in combination with pembrolizumab in the Phase 1 ONKORAS-101 trial for patients with KRASG12C mutant non-small cell lung cancer. BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Ka, resulting in the inhibition of RAS-driven PI3Ka-AKT signaling in tumors without the risk of hyperglycemia. BBO-11818 (NCT06917079) is a panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states with strong potency against KRASG12D and KRASG12V mutants.

Webull offers BridgeBio Oncology Therapeutics Inc stock information, including NASDAQ: BBOT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BBOT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BBOT stock methods without spending real money on the virtual paper trading platform.